Quest Pharmatech

Quest Pharmatech FCF Yield

The Free Cash Flow Yield of Quest Pharmatech (QPT.V) as of Oct 24, 2026 is -3.76 %. In the previous year, Free Cash Flow Yield was -10.09 % — a change of -62.74% (higher).

FCF Yield

-3.76 %

YoY

-62.74%

Last updated:

Free Cash Flow Yield of Quest Pharmatech is 2026 -3.76 % . Free Cash Flow Yield of Quest Pharmatech was 2025 -10.09 % . It decreases by -62.74% higher compared to the previous year.

The Quest Pharmatech FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
-136.17 CAD
Jan 1, 2020
-126.38 CAD
Jan 1, 2021
-50.32 CAD
Jan 1, 2022
-3.37 CAD
Jan 1, 2023
-10.93 CAD
Jan 1, 2024
-6.75 CAD
Jan 1, 2025
-10.09 CAD
Jan 1, 2026
-3.76 CAD
The Quest Pharmatech FCF Yield history
YEARFCF YieldYoY
-3.76 %-62.74%
-10.09 %+49.49%
-6.75 %-38.27%
-10.93 %+224.80%
-3.37 %-93.31%
-50.32 %-60.18%
-126.38 %-7.20%
-136.17 %-5.79%
-144.54 %+58.82%
-91.01 %+80.53%
-50.41 %+31.04%
-38.47 %-0.62%
-38.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quest Pharmatech Stock analysis

What does Quest Pharmatech do? Quest PharmaTech, Inc. operates as a biotechnology company headquartered in Edmonton, Alberta, focusing on the development and commercialization of antibody-based immunotherapeutic products for cancer. The firm aims to improve the quality of life through its proprietary MAb-AR9.6, which targets MUC16 as a diagnostic agent. This asset is licensed from the University of Nebraska Medical Centre and is currently in the late preclinical stage of development. The company generates value through strategic equity positions in specialized biotechnology entities. Quest PharmaTech holds a 42.5% ownership interest in OncoQuest Inc., a firm developing combinatorial immunotherapy products for cancer treatment. OncoQuest utilizes a technology platform featuring a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G and E class, targeting CA125, MUC1, PSA, Her2/neu, CA 19.9, and TAG72 to enhance tumor specific immunity. Additionally, the firm maintains a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer within the Greater China territory. These investments allow Quest PharmaTech to extend its reach into specific geographic and therapeutic segments while leveraging the proprietary technologies and platforms of its partner companies. Quest Pharmatech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Pharmatech stock

Free Cash Flow Yield of Quest Pharmatech is -3.76 % in 2026.

Free Cash Flow Yield of Quest Pharmatech changed from -10.09 % to -3.76 %, representing a -62.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Quest Pharmatech since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Quest Pharmatech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quest Pharmatech

All Key Metrics — Quest Pharmatech